Clinical Trials
12 trialsNCT05052268 2026-05-28
XTX202 in Patients With Advanced Solid Tumors
Xilio Development, Inc.
Phase 1/2 Completed
NCT04083976 2026-05-04
RAGNAR
Janssen Research & Development, LLC
Phase 2 Completed
NCT05580770 2026-05-01
Mirdametinib + BGB-3245 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
Phase 1/2 Terminated
NCT06560632 2026-01-16
POLAR
Repare Therapeutics
Phase 1 Terminated
NCT05147350 2025-12-05
MINOTAUR
Debiopharm International SA
Phase 1 Terminated
NCT06232408 2025-11-21
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
Repare Therapeutics
Phase 1 Terminated
NCT04497116 2025-10-21
TRESR
Repare Therapeutics
Phase 1/2 Completed
NCT05072106 2025-09-16
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT05014828 2025-08-24
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT05109442 2025-08-20
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT02836600 2025-08-07
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT04259450 2025-07-17
Study to Assess AFM24 in Advanced Solid Cancers
Affimed GmbH
Phase 1/2 Terminated